Cure8 research brief
Setons are often used to control sepsis in complex anal fistula, but this study suggests outcomes are worse when Crohn's disease is present, meaning clinicians may view long-term setons as temporary measures in CD rather than definitive solutions.
Colorectal surgeons, gastroenterologists managing perianal Crohn's disease, researchers in fistula treatments, and patients with complex anal fistulas (particularly those with Crohn's).
The authors reviewed 99 patients (73 with CD, 26 non-CD) treated 2013–2022 with setons left in place without planned definitive surgery, and measured one-year "seton failure" (recurrent abscess, new fistula, or need for reintervention). Patients with Crohn's disease had higher one-year seton failure (58% vs.
23%), driven by more new fistula formation and need for additional setons. On multivariate analysis, Crohn's disease, family history of IBD, prior anorectal surgery, and steroid use were associated with increased failure risk. The authors interpret these findings as supporting setons as a temporizing measure rather than definitive therapy in CD.
Retrospective design and limited sample size can affect causal inference. The available text is an abstract-level summary; full paper review would be needed for methodological details and subgroup analyses.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Perianal fistulas in Crohn’s disease are hard to treat and preserving continence is important. Long-term data suggesting laser ablation can achieve sustained healing in some patients are relevant for treatment decisions.
Anal fistulas are a common and often painful complication of Crohn’s disease that usually need medical or surgical treatment. Managing the underlying Crohn’s with biologic therapy is often necessary for fistulas to heal....
Perianal fistulas are a serious complication of Crohn’s disease with limited high-quality trial evidence. This randomized trial suggests ustekinumab may increase the chance of combined clinical and MRI remission at 12...
